膿毒癥是針對感染的宿主反應(yīng)失調(diào)引起的致命性器官功能障礙。該病患者院內(nèi)病死率高達(dá)10%以上，導(dǎo)致臨床治療費用高，醫(yī)療資源消耗大，已經(jīng)對人類健康造成了巨大威脅?？股?、抗病毒藥物、血管活性藥等均用于膿毒癥傳統(tǒng)治療，但尚未有足夠的針對膿毒癥發(fā)病機制的特異性藥物投入臨床實踐。如何及時糾正膿毒癥發(fā)生發(fā)展過程中的全身性炎癥反應(yīng)、凝血功能障礙和免疫功能紊亂，盡早恢復(fù)機體促炎-抗炎動態(tài)平衡，有效改善患者預(yù)后，也成為了膿毒癥治療藥物研究首先要考慮的問題。根據(jù)針對膿毒癥發(fā)病階段和治療目的的不同，膿毒癥特異性治療藥物主要分為針對失控炎癥反應(yīng)的藥物、針對凝血功能障礙的藥物、針對免疫功能抑制的藥物和整體調(diào)節(jié)的現(xiàn)代中藥4大類。主要對上述膿毒癥特異性治療藥物進(jìn)行綜述。

Sepsis has been defined as life-threatening organ dysfunction caused by dysregulated host response to infection, associated with an in-hospital mortality in excess of 10% and leading to high treatment cost and medical resources consumption, has become a huge threat to human health. Antibiotics, antiviral drugs, vasoactive agents, etc. have been used in the traditional therapy of sepsis, but there are also not enough specific therapeutic drugs for clinical practice. How to rectify systemic inflammatory response, coagulation disorders, and immune dysfunction, contributing to return to pro-and anti-inflammatory homeostasis, and improve patient outcomes, is the key problem in anti-sepsis drug development. According to the differences of disease stage and treatment purposes, specific therapeutic drugs for the treatment of sepsis are divided into drugs aiming at uncontrolled inflammatory response, coagulation disorders, immune function inhibition, and modern Chinese medicine. Research progress on those specific therapeutic drugs for the treatment of sepsis are reviewed in this paper.

天津市科技小巨人領(lǐng)軍企業(yè)培育重大項目（14ZXLJSY00230）